Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Wick · SciRah

Researcher profile · Semantic Scholar

M. Wick

Share profile

M. Wick — researcher profile on SciRah

h-index: 22
Works: 142
Citations: 2,839

Most-cited papers

An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma
Y. Drier, M. J. Cotton, K. Williamson, Shawn M. Gillespie +16 more
2016Nature Genetics267 citations Open access
Semantic Scholar
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors
R. Ferrarotto, Y. Mitani, L. Diao, I. Guijarro +16 more
2016Journal of Clinical Oncology222 citations Open access
Semantic Scholar
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
U. Germann, Brinley F Furey, W. Markland, R. R. Hoover +17 more
2017Molecular Cancer Therapeutics204 citations Open access
Semantic Scholar
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Yi Yu, R. Savage, S. Eathiraj, J. Meade +4 more
2015PLoS ONE111 citations Open access
Semantic Scholar
Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling
M. Andersson, M. K. Afshari, Ywonne Andrén, M. Wick +1 more
2017Journal of the National Cancer Institute91 citations Open access
Semantic Scholar
Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer.
X. Puyang, Craig Furman, Guo-Zhu Zheng, Z. Wu +49 more
2018Cancer Discovery80 citations Open access
Semantic Scholar
SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads
Krista Kinneer, John H Meekin, A. Tiberghien, Yu-Tzu Tai +14 more
2018Clinical Cancer Research78 citations
Semantic Scholar
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
E. Cocco, F. Carmona, P. Razavi, H. Won +25 more
2018Science Signaling68 citations Open access
Semantic Scholar
Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma
Joseph Mandelbaum, I. Shestopalov, R. Henderson, N. Chau +3 more
2018Journal of Experimental Medicine67 citations Open access
Semantic Scholar
ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma
M. Andersson, Giovanna Mangiapane, Paloma Tejera Nevado, Alexia Tsakaneli +10 more
2020Oncogenesis50 citations Open access
Semantic Scholar
A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug
Chen Chen, S. Choudhury, Darawalee Wangsa, Chamille J. Lescott +10 more
2017Scientific Reports50 citations Open access
Semantic Scholar
Hyperactivation of TORC1 drives resistance to the pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers
D. Sudhan, A. Guerrero-Zotano, H. Won, P. G. Ericsson +18 more
2020Cancer Cell39 citations Open access
Semantic Scholar
A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors
E. Calvo, J. Soria, Wen W. Ma, Tao Wang +9 more
2016Clinical Cancer Research31 citations
Semantic Scholar
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
Yi Yu, Terence Hall, S. Eathiraj, M. Wick +2 more
2017Anti-Cancer Drugs28 citations Open access
Semantic Scholar
Peloruside A Inhibits Growth of Human Lung and Breast Tumor Xenografts in an Athymic nu/nu Mouse Model
C. Meyer, M. Krauth, M. Wick, J. Shay +4 more
2015Molecular Cancer Therapeutics26 citations Open access
Semantic Scholar
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer
Craig Furman, X. Puyang, Zhaojie Zhang, Z. Wu +23 more
2022Molecular Cancer Therapeutics22 citations Open access
Semantic Scholar
Abstract 4693: The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance
U. Germann, Brinley F Furey, J. Roix, W. Markland +17 more
201521 citations
Semantic Scholar
Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma
K. Warner, Felipe Nör, Gerson A Acasigua, M. Martins +11 more
2016Clinical Cancer Research20 citations Open access
Semantic Scholar
Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ER alphaWTand ER alphaMUTBreast Cancer.
X. Puyang, Craig Furman, Guo-Zhu Zheng, Z.-J. Wu +49 more
201814 citations
Semantic Scholar
Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening
Shizhang Ling, E. Rettig, M. Tan, Xiaofei Chang +7 more
2016International Journal of Oncology11 citations Open access
Semantic Scholar
Using PDX animal models to identify and stratify adenoid cystic carcinoma patients presenting an enhanced response to HDAC inhibitors.
Leticia da Guimarães, L. P. Webber, E. Gaio, Decio Sp +5 more
2023American Journal of Cancer Research8 citations
Semantic Scholar
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers
D. Sudhan, A. Guerrero-Zotano, H. Won, P. G. Ericsson +18 more
2020Cancer Cell8 citations Open access
Semantic Scholar
Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms
C. Walker, Hua Chang, Leah Henegar, T. Kashyap +5 more
2022Frontiers in Oncology6 citations Open access
Semantic Scholar
Neratinib induces estrogen receptor function and sensitizes HER2-mutant breast cancer to anti-endocrine therapy
M. Scaltriti, F. Carmona, Eneda Toska, E. Cocco +7 more
20166 citations
Semantic Scholar
Establishment and characterization of a hormone dependent, PSA/PSMA positive prostate PDX model
M. Wick, M. Quinn, A. Mangold, L. Gamez +7 more
20165 citations
Semantic Scholar
Abstract B181: Association of AKT1E17K and PIK3CAH1047R mutations with efficacy of ARQ 092 in vitro, in vivo and in patients
G. Abbadessa, Yi Yu, S. Eathiraj, J. Meade +7 more
20154 citations
Semantic Scholar
Abstract 1457: Genomic characterization of a PDX model of T-DM1-resistant HER2+ invasive ductal carcinoma using augmented exome sequencing
E. Helman, M. Wick, M. Clark, L. Gamez +9 more
20153 citations
Semantic Scholar
64Cu-DOTA-trastuzumab imaging in a HER2-positive intracranial patient-derived xenograft (PDX) model of breast cancer metastasis
L. Kristensen, C. Nielsen, M. Nedergaard, C. Knudsen +5 more
20162 citations
Semantic Scholar
Abstract P1-13-03: Establishment and characterization of two T-DM1-resistant, ER+/HER2+ breast XPDX models developed sequentially from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a)
George Plasko, J. Flores, A. Simonson, P. Forofontov +9 more
2023Cancer Research1 citations
Semantic Scholar
Nonclinical drug development
C. Takimoto, M. Wick, B. Agoram, D. Jin
2022Atkinson's Principles of Clinical Pharmacology1 citations
Semantic Scholar
Abstract 89: Development and characterization of a panel of orthotopic glioblastoma multiforme (GBM) patient-derived xenograft (PDX) mouse models for drug efficacy evaluation
C. H. Nielsen, M. Z. Alfsen, M. Wick, M. Rundle +6 more
2019Tumor Biology1 citations Open access
Semantic Scholar
Abstract 4816: Anetumab ravtansine has monotherapy efficacy in mesothelin positive patient-derived NSCLC tumor models and in a syngeneic tumor model in immunocompetent mice
A. Sommer, P. Lejeune, S. Hoff, A. Walter +7 more
2019Experimental and Molecular Therapeutics1 citations
Semantic Scholar
Abstract A138: Loss of the lysosomal transporter SLC46A3 is a mechanism for innate and acquired resistance to non-cleavable maytansine and pyrrolobenzodiazepine-based antibody-drug conjugates
Krista Kinneer, John H Meekin, Sandrina S. Phipps, Binyam Z Bezabeh +12 more
20181 citations
Semantic Scholar
Abstract 158: ASN003, a highly selective inhibitor of B-Raf and PI3 kinases, shows strong antitumor activity in B-Raf inhibitor resistant patient-derived xenograft models
S. Thompson, R. Smith, N. Rao, M. Wick +1 more
20171 citations
Semantic Scholar
481 In vitro and vivo evaluation of the pan FGFR inhibitor ARQ 087 and selective pan AKT inhibitor ARQ 092 in endometrial cancer: potential for combination therapy
J. Meade, M. Wick, T. Vaught, R. Chavez +9 more
20141 citations
Semantic Scholar
96 Evaluation of hormone therapies in a panel of breast PDX models: Relevance of ER status on sensitivity to letrozole and tamoxifen
M. Wick, T. Vaught, L. Gamez, J. Meade +7 more
20141 citations
Semantic Scholar
Non-Clinical Drug Development
C. Takimoto, M. Wick
20131 citations
Semantic Scholar
Abstract P1-13-22: Establishment and characterization of two ER+/HER2- XPDX models developed sequentially before and after acquired resistance to the CDK4/6 inhibitor palbociclib from a patient with metastatic breast cancer
Ashwin Varma, J. Flores, A. Simonson, A. Stackpole +6 more
2023Cancer Research0 citations
Semantic Scholar
Abstract P3-08-05: Correlation of Trop2 expression with in vivo sensitivity to sacituzumab govitecan in a panel of breast XPDX models
A. Simonson, J. Flores, E. Anderson, C. Moreno +19 more
2023Cancer Research0 citations
Semantic Scholar
Abstract 183: Ex vivo 3D drug response profiling of XPDX-derived tumor cells for acceleration of preclinical drug development
A. L. Carlson, Ashley K. Elrod, Natalie A. Williams, A. Moriarty +2 more
2022Cancer Research0 citations
Semantic Scholar
Abstract 177: Ex vivo 3D culture of adenoid cystic carcinoma PDX models recapitulate disease biomarkers and predict drug response
Melissa Millard, T. DesRochers, M. Wick, Jeffrey R. Kaufman +1 more
2022Cancer Research0 citations Open access
Semantic Scholar
Contributors
D. Abernethy, B. Agoram, John M. Allen, Mark E. Arnold +82 more
2022Atkinson's Principles of Clinical Pharmacology0 citations
Semantic Scholar
Predictive factors for successful growth of patient derived xenografts (PDX).
T. Hernández-Guerrero, B. Doger, J. García-Foncillas, M. Wick +1 more
2022Journal of Clinical Oncology0 citations
Semantic Scholar
Abstract 353: Establishment and characterization of neuregulin-1 (NRG1) fusion driven XPDX models
A. Simonson, J. Flores, C. Moreno, Justine Hruzek +7 more
2022Cancer Research0 citations
Semantic Scholar
Abstract 1092: Correlation of platinum sensitivity with donor patient treatment status in a panel of breast, ovary, uterine, and lung XPDX models
A. Simonson, J. Flores, Lizette Firova, C. Hernández +10 more
2022Cancer Research0 citations
Semantic Scholar
Abstract 412: Correlation of drug sensitivity to clinical response in XPDX models established from patients treated with KRAS-G12C-inhibitor therapy
J. Flores, A. Simonson, P. Forofontov, A. Stackpole +8 more
2022Cancer Research0 citations
Semantic Scholar
Abstract P5-01-04: Correlation of HER2 receptor expression and in vivo activity of the HER2-targeting therapies trastuzumab deruxtecan (DS-8201a) and T-DM1 activity in a panel of breast XPDX models
A. Simonson, P. Forofontov, J. Flores, Kimberly Hernandez +15 more
2022Cancer Research0 citations
Semantic Scholar
Abstract P5-01-06: Establishment and characterization of luminal A breast XPDX models from patients with acquired resistance to CDK 4/6 inhibitors
T. Hernandez, D. Kneifel, A. Simonson, J. Flores +11 more
2022Cancer Research0 citations
Semantic Scholar
Abstract P5-01-09: Establishment and characterization of two simultaneously developed T-DM1-resistant, ER+/HER2+ XPDX models from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a)
J. Flores, A. Stackpole, Abimael Garza, Alexandra Ulmer +10 more
2022Cancer Research0 citations
Semantic Scholar
Abstract P5-01-11: Nonclinical activity of fulvestrant in a panel of ER+ breast XPDX models representing clinically acquired and innate resistance to endocrine therapies
April B. Cabang, C. Moreno, J. Flores, Jenna Boedeker +15 more
2022Cancer Research0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. Papadopoulos×20
Invite
K. Papadopoulos — researcher profile on SciRah
A. Patnaik×13
Invite
A. Patnaik — researcher profile on SciRah
J. Flores×10
Invite
J. Flores — researcher profile on SciRah
A. Simonson×10
Invite
A. Simonson — researcher profile on SciRah

×10

Invite

D. Rasco — researcher profile on SciRah

Invite

A. Lang — researcher profile on SciRah

Invite

M. Beeram — researcher profile on SciRah

Invite

A. Moriarty — researcher profile on SciRah

Invite

A. Tolcher — researcher profile on SciRah

G. Rodriguez×6

Invite

G. Rodriguez — researcher profile on SciRah

Invite

R. Drengler — researcher profile on SciRah

Invite

L. Smith — researcher profile on SciRah